Lucid Diagnostics Inc (NASDAQ: LUCD) on Monday, soared 5.76% from the previous trading day, before settling in for the closing price of $1.39. Within the past 52 weeks, LUCD’s price has moved between $0.63 and $1.63.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 129.86% annually for the last half of the decade. The company achieved an average annual earnings per share of 84.26%. With a float of $31.75 million, this company’s outstanding shares have now reached $51.60 million.
In an organization with 70 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -85.49%, operating margin of -1077.37%, and the pretax margin is -1069.9%.
Lucid Diagnostics Inc (LUCD) Insider and Institutional Ownership
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Lucid Diagnostics Inc is 62.03%, while institutional ownership is 5.40%.
Lucid Diagnostics Inc (LUCD) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 84.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 58.74% during the next five years compared to -110.66% drop over the previous five years of trading.
Lucid Diagnostics Inc (NASDAQ: LUCD) Trading Performance Indicators
Lucid Diagnostics Inc (LUCD) is currently performing well based on its current performance indicators. A quick ratio of 1.11 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.13, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.63 in one year’s time.
Technical Analysis of Lucid Diagnostics Inc (LUCD)
Let’s dig in a bit further. During the last 5-days, its volume was 0.74 million. That was better than the volume of 0.59 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 63.87%. Additionally, its Average True Range was 0.14.
During the past 100 days, Lucid Diagnostics Inc’s (LUCD) raw stochastic average was set at 81.54%, which indicates a significant increase from 78.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 101.85% in the past 14 days, which was higher than the 70.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1346, while its 200-day Moving Average is $0.9156. However, in the short run, Lucid Diagnostics Inc’s stock first resistance to watch stands at $1.5367. Second resistance stands at $1.6033. The third major resistance level sits at $1.7067. If the price goes on to break the first support level at $1.3667, it is likely to go to the next support level at $1.2633. The third support level lies at $1.1967 if the price breaches the second support level.
Lucid Diagnostics Inc (NASDAQ: LUCD) Key Stats
Market capitalization of the company is 122.94 million based on 59,342K outstanding shares. Right now, sales total 2,430 K and income totals -52,670 K. The company made 1,170 K in profit during its latest quarter, and -12,370 K in sales during its previous quarter.
